Laurent Chardonnet - 01 Mar 2024 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Reporting relationship: Chief Financial Officer
Issuer ticker: PRLD
Reported as of: 01 Mar 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Mar 2024, 18:04:08 UTC
Prior SEC filing: 25 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Laurent Chardonnet

Key filing fact

Laurent Chardonnet filed Form 4 for Prelude Therapeutics Inc (PRLD) on 04 Mar 2024.

Key facts

This page summarizes Laurent Chardonnet's Form 4 filing for Prelude Therapeutics Inc (PRLD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Mar 2024, 18:04.

Change

Previous filing in this sequence was filed on 25 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRLD transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +150,000
Change %
Price: $0.000000
Shares after: 150,000
Date: 01 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $4.59
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.